CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Tysabridrug
Likely dose
Tysabri 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01071512
NCT01071512N/ACompleted
CompareCT.gov

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

University of Chicago·interventional·Posted Feb 19, 2010·Updated Oct 25, 2017

In Brief

A clinical study evaluating Tysabri for Multiple Sclerosis. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The long-term objective is to further establish the role of Tysabri in preventing neurological degeneration in multiple sclerosis (MS) and to establish powerful and efficient new markers for neurological degeneration in MS. The study intends to correlate cognition with two instruments and their measurements-MRI and OCT (optical coherence tomography).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsBiogen

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 19, 2010
Enrollment StartApr 1, 2010
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 16.4 years ago

Interventions

Tysabridrug

Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.